Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
2024年1月8日 - 4:30PM
ビジネスワイヤ(英語)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational
pharmaceutical company, today announced an agreement to promote
Guardant Health’s portfolio of liquid and tissue biopsy tests for
cancer screening, recurrence monitoring and tumor mutation
profiling across all solid cancers in countries across the Middle
East and North Africa (MENA).
The partnership expands Guardant Health’s global presence and
includes products across the cancer care continuum. The tests
offered include Shield™ for cancer screening and early detection,
Guardant Reveal™ for minimal residual disease detection and
recurrence monitoring, and Guardant360® and Guardant360 TissueNext™
for comprehensive genomic profiling across all solid cancers.
Guardant Health serves more than 60 countries globally with its
tests, and this partnership with Hikma will improve access to
Guardant’s next-generation sequencing (NGS) tests in the Middle
East and North Africa, where cancer cases are estimated to double
by the year 2040.1
“Guardant Health is excited to partner with Hikma and leverage
their strong commercial capabilities and regional expertise to
equip oncologists in MENA with the necessary tools for cancer
screening, recurrence monitoring and guiding treatment selection,”
said Simranjit Singh, Guardant Health AMEA CEO. “We are committed
to improving patient outcomes globally by offering next-generation
sequencing tests across all stages of the disease. Today, an
increasing number of patients with cancer are being detected at the
advanced stage, making it more crucial to match these patients to
appropriate therapies in a timely manner. Ultimately, our goal is
to make cancer screening easy and effective so that we can detect
cancer earlier when it's most treatable.”
“Our partnership with Guardant Health adds next-generation
sequencing diagnostics that can potentially transform cancer care
in MENA bringing hope to patients facing this challenging journey.
We are excited to partner with Guardant Health, as their offering
can help patients at all stages of the disease – from screening to
monitoring cancer recurrence to guiding treatment decisions. As a
leading healthcare company in MENA with a robust oncology portfolio
encompassing generics, biologics, immunotherapy, and cutting-edge
innovations, Hikma is committed to advancing precision medicine for
improved treatment outcomes in patients with cancer," said Mazen
Darwazah, Hikma’s executive vice chairman and president of
MENA.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable
S&P and BBB-/positive Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 45 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across North America, the Middle East
and North Africa (MENA) and Europe, and we use our unique insight
and expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively
and acting practically, we provide them with a broad range of
branded and non-branded generic medicines. Together, our 8,800
colleagues are helping to shape a healthier world that enriches all
our communities. We are a leading licensing partner, and through
our venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit: www.hikma.com
Reference 1. Mahdi H, Mula-Hussain L, Ramzi ZS, et al.
Cancer Burden Among Arab-World Females in 2020: Working Toward
Improving Outcomes. JCO Glob Oncol. 2022;8:e2100415.
doi:10.1200/GO.21.00415
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240107941841/en/
Hikma Pharmaceuticals
PLC
Susan Ringdal EVP, Strategic Planning and Global Affairs +44
(0)20 7399 2760/ +44 7776 477050 uk-investors@hikma.uk.com
Mona Abdallah Senior Director, MENA Communications + 962 6
5802900 MBAbdallah@Hikma.com
Guardant Health
Investor Contact: investors@guardanthealth.com
Media Contacts:
Melissa Marasco Senior Corporate Communications Manager
press@guardanthealth.com +1 650-647-3711
Prakash Raja Senior Manager Communications AMEA
press_amea@guardanthealth.com +65 90051001
Hikma Pharmaceuticals (LSE:HIK)
過去 株価チャート
から 4 2024 まで 5 2024
Hikma Pharmaceuticals (LSE:HIK)
過去 株価チャート
から 5 2023 まで 5 2024